← Back to Search

Radiation Therapy

SMART for Lung Cancer

Led By Saumil Gandhi, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Central tumors ≤ 2 cm from any mediastinal critical structure (proximal bronchial tree, esophagus, heart, brachial plexus, major vessels, spinal cord, phrenic nerve, and recurrent laryngeal nerve)
Determined by two thoracic radiation oncologists to require > 10-15 fraction regimens if treated with CT-based, non-adaptive radiation therapy
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Study Summary

This trial compares radiation therapy guided by MRI vs CT to see if it helps control central lung cancer.

Who is the study for?
This trial is for adults with central lung tumors close to critical structures who can sign consent. It's for those needing more than 10-15 radiation sessions if using CT-based therapy, and includes primary or metastatic lung cancer patients. Pregnant women, individuals unable to undergo MRI due to claustrophobia or metal implants, and those not using contraception are excluded.Check my eligibility
What is being tested?
The study tests Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) against conventional CT-guided therapy in controlling central lung cancer. The goal is to see if MRI guidance improves treatment precision and effectiveness compared to the usual method.See study design
What are the potential side effects?
Potential side effects of SMART may include skin reactions, fatigue, shortness of breath, coughing, chest pain, difficulty swallowing due to esophagus irritation from radiation exposure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
The tumor is located very close to important structures in the chest.
Two doctors specializing in chest radiation agree that you need to receive radiation treatments in more than 10-15 sessions using a specific type of radiation therapy.
You have cancer that started in the lungs or cancer that has spread to the lungs from another part of the body.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0, Change From Baseline in Pain Scores on the Visual Analog Scale at 6 Weeks

Trial Design

2Treatment groups
Experimental Treatment
Group I: Stage II (Stereotactic MRI-guided adaptive radiotherapy-SMART)Experimental Treatment1 Intervention
Participants will receive treatment with the investigational MRI-guided radiation therapy.
Group II: Stage I-(Simulated Online Adaptive Planning)Experimental Treatment1 Intervention
Participants will receive treatment with the conventional CT-based radiation therapy and receive additional MRI scans.

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,966 Previous Clinical Trials
1,804,761 Total Patients Enrolled
Saumil Gandhi, MDPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
75 Total Patients Enrolled

Media Library

Stereotactic MRI-guided adaptive radiotherapy-SMART (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05609331 — N/A
Lung Cancer Research Study Groups: Stage I-(Simulated Online Adaptive Planning), Stage II (Stereotactic MRI-guided adaptive radiotherapy-SMART)
Lung Cancer Clinical Trial 2023: Stereotactic MRI-guided adaptive radiotherapy-SMART Highlights & Side Effects. Trial Name: NCT05609331 — N/A
Stereotactic MRI-guided adaptive radiotherapy-SMART (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05609331 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the recruitment count for this research trial?

"Affirmative. Clinicaltrials.gov lists this medical trial as actively recruiting, with the original posting date of November 17th 2022 and a subsequent update on that same day. The researchers are in search of 20 patients from 1 test centre."

Answered by AI

Are there any vacancies left in this research program for volunteers?

"According to clinicaltrials.gov, this medicinal trial is actively recruiting patients since its initial post on November 17th 2022 and most recent update the same date."

Answered by AI
~9 spots leftby Apr 2025